Gerd Munzert serves as Chief Medical Officer of NBE Therapeutics since June 2021. Gerd is a hematologist and medical oncologist with more than 20 years of experience in anticancer drug development.

Gerd has worked in different roles for Boehringer Ingelheim Oncology. He successfully led and steered clinical development of NCEs such as antimitotic kinases, EGFR tyrosine kinases and other targeted agents. Prior to taking on the position of the CMO, Gerd was responsible for early preclinical and clinical programmes, translational plans and external collaborations within Boehringer Ingelheim Oncology.

He attended medical school in Freiburg and Munich and did postdoctoral research at the University of Michigan, working on G-protein receptors in the lab of Prof. T. Yamada. In his further academic career, he focused on pathophysiology and treatment of leukemias and lymphomas at Ulm University where he maintains an affiliation as a lecturer.